Enliven Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.55 | -$0.55 | -$0.55 |
| Q2 2024 | 1 | -$0.50 | -$0.50 | -$0.50 |
| Q3 2024 | 2 | -$0.59 | -$0.48 | -$0.52 |
| Q1 2025 | 2 | -$0.56 | -$0.56 | -$0.56 |
| Q2 2025 | 1 | -$0.58 | -$0.58 | -$0.58 |
| Q3 2025 | 1 | -$0.64 | -$0.64 | -$0.64 |
| Q4 2025 | 1 | -$0.60 | -$0.60 | -$0.60 |
Enliven Therapeutics, Inc. Earnings Date And Information
Enliven Therapeutics, Inc. last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.48 earnings per share for the quarter, topping analysts' consensus estimates of $-0.52 by $0.04. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Enliven Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.01 diluted earnings per share) and currently has a price-to-earnings ratio of -14.51. Enliven Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based on prior year's report dates.
Enliven Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.52 | -$0.48 | 0.04 | $0 | $0 |
| 08/13/2024 | Q2 2024 | -$0.58 | -$0.42 | 0.17 | $0 | $0 |
| 05/14/2024 | Q1 2024 | -$0.58 | -$0.54 | 0.04 | $0 | |
| 03/14/2024 | Q4 2023 | -$0.56 | -$0.47 | 0.09 | $440,000 | |
| 09/29/2023 | Q3 2023 | -$0.51 | $0 | |||
| 06/30/2023 | Q2 2023 | -$0.41 | $0 | |||
| 03/31/2023 | Q1 2023 | -$0.80 | $0 | |||
| 02/10/2023 | Q4 2022 | $4.90 | $0 | |||
| 10/25/2022 | Q3 2022 | -$1.00 | -$0.70 | 0.3 | $0 | |
| 06/29/2022 | Q2 2022 | -$1.74 | $0 | |||
| 03/30/2022 | Q1 2022 | -$2.23 | $0 | |||
| 12/30/2021 | Q4 2021 | -$2.18 | $0 | |||
| 11/09/2021 | Q3 2021 | -$3.38 | -$2.19 | 1.19 | $0 | |
| 08/06/2021 | Q2 2021 | -$3.20 | -$2.97 | 0.23 | $0 | |
| 05/11/2021 | Q1 2021 | -$3.34 | -$2.33 | 1.01 | $0 | |
| 03/05/2021 | Q4 2020 | -$3.35 | -$2.63 | 0.72 | $0 | |
| 11/05/2020 | Q3 2020 | -$3.21 | -$2.86 | 0.35 | $0 | |
| 08/14/2020 | Q2 2020 | -$2.25 | -$2.37 | -0.12 | $0 | |
| 05/07/2020 | Q1 2020 | -$2.94 | -$3.64 | -0.7 | $0 | |
| 12/30/2019 | Q4 2019 | -$1.68 | $0 |
Enliven Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Enliven Therapeutics, Inc.'s earnings date?
Enliven Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based off last year's report dates.
-
Did Enliven Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Enliven Therapeutics, Inc. (:ELVN) reported $-0.48 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.52 by $0.04.
-
How can I listen to Enliven Therapeutics, Inc.'s earnings conference call?
The conference call for Enliven Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Enliven Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Enliven Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Enliven Therapeutics, Inc. generate each year?
Enliven Therapeutics, Inc. (:ELVN) has a recorded net income of $0. Enliven Therapeutics, Inc. has generated $-2.01 earnings per share over the last four quarters.
-
What is Enliven Therapeutics, Inc.'s price-to-earnings ratio?
Enliven Therapeutics, Inc. (:ELVN) has a price-to-earnings ratio of -14.51 and price/earnings-to-growth ratio is -0.55.
